NASDAQ$SYRE
Spyre Therapeutics Inc · Q4 2023 earnings
Q4 2023 earnings · · Investor relations
Briefing
Spyre Therapeutics reported its financial results for the fourth quarter and full year 2023, along with corporate and program updates.
Spyre Therapeutics announced its fourth quarter and full year 2023 financial results, highlighting the advancement of its IBD therapies and a strong cash position of $339.6 million. The company is progressing with clinical studies across multiple programs and anticipates Phase 2 evaluation of rational therapeutic combinations in IBD patients in 2025.
- Corporate name changed to Spyre Therapeutics and began trading on Nasdaq under the symbol 'SYRE'.
- SPY001 demonstrated an updated half-life of 22 days, a greater than three-fold increase relative to vedolizumab in non-human primate pharmacokinetic data.
- SPY002 remains on track to begin first-in-human studies in the second half of 2024.
- Raised $180 million in private placement equity financing, extending cash runway into the second half of 2026.
Headline financials
Revenue & EPS history
Spyre · Revenue · Quarterly
$0
Forward guidance
Spyre Therapeutics is focused on advancing its pipeline of IBD therapies, with multiple clinical studies planned and potential best-in-class properties of its investigational medicines anticipated.
Tailwinds
- Initiating Phase 2 evaluation of rational therapeutic combinations in IBD patients in 2025.
- SPY001 is expected to enter first-in-human studies in the first half of 2024, with interim proof-of-concept data expected year-end 2024.
- SPY002 remains on track to begin first-in-human studies in the second half of 2024.
- Advancing a potential best-in-class IL-23 monoclonal antibody.
- Cash runway extended into the second half of 2026.
Headwinds
- Potential impacts of macroeconomic conditions, including inflationary pressures and rising interest rates.
- General economic slowdown or a recession.
- Changes in monetary policy.
- The prospect of a shutdown of the U.S. federal government.
- Volatile market conditions and financial institution instability.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 20 quarterly earnings reports · overlaid with Q4 2023
-0.4%
Avg return
Earnings day
+1.3%
Avg return
5 days after
+2.3%
Avg return
30 days after
44%
17 / 39 earnings
Positive
+14.6%
Q4 2023
Best reaction
-10.9%
Q1 2022
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | +2.6% | +7.6% | +3.6% | |
| Q3 2025 | +0.5% | +4.6% | +49.4% | |
| Q1 2025 | -2.0% | -0.7% | +13.2% | |
| Q4 2024 | +7.2% | +6.0% | -2.3% | |
| Q3 2024 | +5.6% | -4.4% | -27.7% | |
| Q2 2024 | -3.0% | -6.6% | +7.4% | |
| Q1 2024 | +11.8% | +19.0% | +2.0% | |
| Q4 2023 | +14.6% | +44.3% | +45.3% | |
| Q3 2023 | -2.2% | +10.8% | +102.2% | |
| Q2 2023 | -10.3% | -12.0% | +6.7% | |
| Q1 2023 | -6.6% | -9.1% | -18.3% | |
| Q4 2022 | -0.3% | +2.0% | -26.6% | |
| Q3 2022 | -9.0% | +3.7% | -59.0% | |
| Q2 2022 | +7.7% | +5.9% | +33.3% | |
| Q1 2022 | -10.9% | -5.8% | -60.0% | |
| Q4 2021 | +0.4% | -14.6% | +14.2% | |
| Q3 2021 | -5.4% | -5.8% | -22.5% | |
| Q2 2021 | -0.6% | -3.3% | +12.1% | |
| Q1 2021 | +2.2% | +4.4% | -8.1% | |
| Q4 2020 | +1.7% | +9.7% | +5.3% | |
| Q3 2020 | +4.5% | +22.1% | +3.5% | |
| Q2 2020 | -6.7% | -4.7% | +3.2% | |
| Q1 2020 | +10.6% | -4.5% | +24.0% | |
| Q4 2019 | -8.3% | -13.2% | -40.2% | |
| Q3 2019 | -4.3% | -2.2% | -4.1% | |
| Q2 2019 | -4.1% | -3.8% | -0.5% | |
| Q1 2019 | -1.9% | -2.1% | -8.7% | |
| Q4 2018 | -0.7% | +3.1% | +8.8% | |
| Q3 2018 | +0.2% | -13.0% | -13.3% | |
| Q2 2018 | +4.8% | +1.2% | -3.4% | |
| Q1 2018 | +3.5% | +0.6% | +4.0% | |
| Q4 2017 | -1.4% | +23.7% | +20.5% | |
| Q3 2017 | -4.9% | +4.5% | +0.0% | |
| Q2 2017 | -6.3% | -7.2% | +34.8% | |
| Q1 2017 | -2.2% | -2.0% | -43.4% | |
| Q4 2016 | -4.4% | -6.9% | -8.7% | |
| Q3 2016 | -1.2% | +1.3% | -7.5% | |
| Q2 2016 | +1.1% | -1.9% | +48.2% | |
| Q1 2016 | +0.7% | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro